前期本刊专栏曾指出,含有保泰松的产品用途已限制用于关节强直性脊椎炎的治疗,且只供应医院使用。保泰松与羟基保泰松已受到英国药品安全委员会的监督。委员会已进一步向主管执照当局建议:凡含有羟基保泰松的产品应吊销生产许可执照。由于这一建议的结果,接着药厂向委员会上诉 Previous issue of this column has pointed out that the use of products containing phenylbutazone has been limited to the treatment of ankylosing spondylitis, and only for hospital use. Phenylbutazone and hydroxybuthylaxis have been supervised by the British Drug Safety Board. The Committee has further advised the competent licensing authority that a license for production licenses should be revoked for products containing oxyphenbutazone. As a result of this suggestion, the pharmaceutical factory appealed to the committee